Targeting human CD27 with an agonist antibody stimulates T-cell activation and antitumor immunity

OncoImmunology

Volumn 3, Issue 1, 2014, Pages

  Thomas, Lawrence J ^a   He, Li Zhen ^a   Marsh, Henry ^a   Keler, Tibor ^a  

^a Celldex Therapeutics Inc   (United Kingdom)

Author keywords

CD27; Co stimulation; Fc receptors; Immunotherapy; Monoclonal antibody

Indexed keywords

ANTINEOPLASTIC AGENT; CD27 ANTIGEN; GAMMA INTERFERON; VARLILUMAB;

ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL PROLIFERATION; CELL STIMULATION; CYTOKINE RELEASE; CYTOKINE RESPONSE; DRUG MECHANISM; DRUG TARGETING; HUMAN; IMMUNOSTIMULATION; NONHUMAN; T LYMPHOCYTE ACTIVATION;

EID: 84899106517     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.27255     Document Type: Article

References (10)

1. Denoeud J, Moser M. Role of CD27/CD70 pathway of activation in immunity and tolerance. J Leukoc Biol 2011; 89:195-203; PMID:20699361; http://dx.doi.org/10.1189/jlb.0610351.
2. French RR, Taraban VY, Crowther GR, Rowley TF, Gray JC, Johnson PW, Tutt AL, Al-Shamkhani A, Glennie MJ. Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation. Blood 2007; 109:4810-5; PMID:17311995; http://dx.doi.org/10.1182/blood-2006-11-057216.
3. Vitale LA, He L-Z, Thomas LJ, Widger J, Weidlick J, Crocker A, O'Neill T, Storey J, Glennie MJ, Grote DM, et al. Development of a human monoclonal antibody for potential therapy of CD27-expressing lymphoma and leukemia. Clin Cancer Res 2012; 18:3812-21; PMID:22589397; http://dx.doi. org/10.1158/1078-0432.CCR-11-3308.
4. He L-Z, Prostak N, Thomas LJ, Vitale L, Weidlick J, Crocker A, Pilsmaker CD, Round SM, Tutt A, Glennie MJ, et al. Agonist anti-human CD27 monoclonal antibody induces T cell activation and tumor immunity in human CD27-transgenic mice. J Immunol 2013; 191:4174-83; PMID:24026078; http://dx.doi.org/10.4049/jimmunol.1300409.
5. Duff GW, et al. Expert Scientific Group on Phase One Clinical Trials (a.k.a. "The Duff Report") 2006 www.tsoshop.co.uk.
6. Waibler Z, Sender LY, Merten C, Hartig R, Kliche S, Gunzer M, Reichardt P, Kalinke U, Schraven B. Signaling signatures and functional properties of anti-human CD28 superagonistic antibodies. PLoS One 2008; 3:e1708; http://dx.doi.org/10.1371/journal. pone.0001708; PMID:18320029.
7. Claus C, Riether C, Schürch C, Matter MS, Hilmenyuk T, Ochsenbein AF. CD27 signaling increases the frequency of regulatory T cells and promotes tumor growth. Cancer Res 2012; 72:3664-76; PMID:22628427; http://dx.doi.org/10.1158/0008-5472.CAN-11-2791.
8. Aulwurm S, Wischhusen J, Friese M, Borst J, Weller M. Immune stimulatory effects of CD70 override CD70-mediated immune cell apoptosis in rodent glioma models and confer long-lasting antiglioma immunity in vivo. Int J Cancer 2006; 118:1728-35; PMID:16217761; http://dx.doi.org/10.1002/ijc.21544.
9. Sakanishi T, Yagita H. Anti-tumor effects of depleting and non-depleting anti-CD27 monoclonal antibodies in immune-competent mice. Biochem Biophys Res Commun 2010; 393:829-35; PMID:20171165; http://dx.doi.org/10.1016/j.bbrc.2010.02.092.
10. Roberts DJ, Franklin NA, Kingeter LM, Yagita H, Tutt AL, Glennie MJ, Bullock TNJ. Control of established melanoma by CD27 stimulation is associated with enhanced effector function and persistence, and reduced PD-1 expression of tumor infiltrating CD8(+) T cells. J Immunother 2010; 33:769-79; PMID:20842060; http://dx.doi.org/10.1097/CJI.0b013e3181ee238f.